Document is current
Any future updates will be listed below
-
Authors
Colunga-Biancatelli, Ruben M. L.
Solopov, Pavel A.
Woodson, Caitlin M.
Allen, Irving Coy
Akhrymuk, Ivan
Akhrymuk, Maryna
Heath, Brittany N.
Ivester, Hannah M.
Day, Tierney
Austin, Dan E.
Kehn-Hall, Kylene
Lazo, John S.
Sharlow, Elizabeth R.
Catravas, John D.
-
Funding
Funding for this research was provided by:
National Institutes of Health (CCF22-0064-PS ; R43-HL158409-01A1 ; R43-HL158409-01A1S1 ; R43-HL158409-01A1S2 ;)
National Institutes of Health (CCF22-0064-PS ; R43-HL158409-01A1 ; R43-HL158409-01A1S1 ; R43-HL158409-01A1S2 ;)
National Institutes of Health (CCF22-0064-PS ; R43-HL158409-01A1 ; R43-HL158409-01A1S1 ; R43-HL158409-01A1S2 ;)
- License Information
-
More Information
Article History
Received: 9 April 2025
Accepted: 19 August 2025
First Online: 28 October 2025
Declarations
:
: Not applicable.
: Not applicable.
: John S. Lazo and Elizabeth R. Sharlow are co-inventors of U.S. Patent No. 10,308,663, which describes the chemical synthesis, composition of matter and use of KVX-053 for the treatment of cancer. A provisional US patent application entitled “Composition and methods for treating/preventing lung injury” (Serial No. PCT/US2022/024927) and an European Union patent application (22788973.0) with the same title have been filed with John S. Lazo, Elizabeth R. Sharlow, John D. Catravas, Ruben M.L. Colunga Biancatelli, and Pavel A. Solopov being listed as co-inventors. John S. Lazo and Elizabeth Sharlow are co-founders of KeViRx, Inc, which has licensed the above-mentioned intellectual property from the University of Virginia, University of Pittsburgh, and Old Dominion University for further development.
